As organisations concerned with the current and future wellbeing of our rapidly ageing society, the International Longevity Centre – UK (ILC-UK) and the International Federation on Ageing (IFA) have conducted a great deal of work on the burden of pneumococcal disease across the life-course.

We believe that the UK’s immunisation programme over recent years has been very successful in reducing incidences of Invasive Pneumococcal Disease (IPD), a major cause of death globally.

However, in October 2017 the Joint Committee on Vaccination and Immunisation (JCVI) suggested that the childhood vaccination for pneumococcal disease should move from a 2+1 schedule (two initial doses and a follow-up dose) to a 1+1 schedule (one initial dose and a follow-up).

We were concerned to hear from the JCVI’s reports that “moving to a 1+1 schedule might increase IPD cases in infants because of loss of direct protection, and in older adults because of a reduction in herd immunity as a result of less protection against carriage in infants after a single dose.”

We would welcome more detailed research into the potential increase in cases of invasive pneumococcal disease in children and adults that might occur from a change to the pneumococcal immunisation programme, to a ‘1 + 1’ schedule.

Given the potential risks of this decision, we would urge a fuller consultation on proposed changes to the pneumococcal immunisation programme. Perhaps an expert sub-committee of JCVI could be convened to review the evidence before a final decision is made.

Finally, to declare an interest, ILC-UK’s work on immunisation has been financially supported (through non-restricted educational grants) by a range of pharmaceutical companies who may have an interest in this area including SPMSD, Eli Lilly, and Pfizer and the IFA’s work on immunisation has been supported similarly by Pfizer and GSK through unrestricted educational grants.


David Sinclair                           Jane Barratt
Director                                  Secretary General
ILC-UK                                   International Federation on Ageing


A thriving older population is being failed by products and services which have been left behind by their changing needs, finds a new Commission set up by specialist think tank ILC-UK with support from Audley Group and EY.

Commenting on the latest data from the ONS which suggests life expectancy progress in the UK 'stops for the first time', Jon Date, Head of External Affairs at the specialist think tank the International Longevity Centre - UK (ILC-UK), said:

Two new keynote speakers announced for 29th November - Michael Kreft von Byern of Europa Park and Norwegian Minister for the Elderly and Public Health Åse Michaelsen

New data analysis reveals the vast market for health apps – including the 760,000 ‘living fast, dying young’ under 40s who smoke, drink frequently, have a smart phone and regularly use the internet.

We are recruiting for a temporary Events Coordinator to coordinate and support our busy events calendar for the remainder of 2018, build on our external communications and assist the Head of External Affairs on communications around our Future of Ageing conference.

New international report explores the relationship between life expectancy and productivity in developed countries.